| P2093 | author name string | Firdevs Topal | |
| | Emrah Alper | |
| | Fatih Aslan | |
| | Belkıs Ünsal | |
| | Elif Sarıtaş Yüksel | |
| | Cem Çekiç | |
| | Sezgin Vatansever | |
| | Ayşe Dallı | |
| P2860 | cites work | Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. | Q51227130 |
| | The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. | Q51242162 |
| | Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. | Q51812401 |
| | Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis | Q57213579 |
| | Tuberculosis after Solid‐Organ Transplant: Incidence, Risk Factors, and Clinical Characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort | Q57569151 |
| | Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis | Q79253031 |
| | Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay | Q80651297 |
| | Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis | Q81898770 |
| | Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience | Q82256081 |
| | Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases | Q84768713 |
| | Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis | Q84911580 |
| | Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors | Q84973671 |
| | Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia | Q33667789 |
| | Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review | Q34455442 |
| | The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement | Q34660076 |
| | BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment | Q35537181 |
| | Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis | Q36058870 |
| | Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment | Q36154640 |
| | An update on the diagnosis of tuberculosis infection | Q36518580 |
| | Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. | Q37980410 |
| | Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. | Q38194708 |
| | Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade | Q40107449 |
| | Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers | Q40160830 |
| | Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening | Q42238439 |
| | How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study | Q42437188 |
| | Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis | Q43257889 |
| | Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha | Q46217008 |
| | Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. | Q46276138 |
| | The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients | Q46718684 |
| | Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? | Q47394976 |
| | Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease | Q47412676 |
| | Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. | Q47652162 |
| | High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy | Q47808177 |
| | Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis. | Q51201277 |
| P433 | issue | 2 | |
| P921 | main subject | tuberculosis | Q12204 |
| | inflammatory bowel diseases | Q917447 |
| | latent tuberculosis | Q4254929 |
| P304 | page(s) | 241-246 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Annals of Gastroenterology | Q15758811 |
| P1476 | title | Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy | |
| P478 | volume | 28 | |